DXRX Diaceutics PLC
Diaceutics PLC, a diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies. The company offers DXRX, a diagnostic commercialization platform for precision medicine that integrates multiple pipelines of diagnostic testing data from a network of laboratories. It also provides DXRX data solutions, including DXRX Signal, that enables potential therapy eligibility for patients within hours of a diagnostic event, enabling teams to act while treatment decisions are still pending; DXRX Physician Mapping that examines physician testing behavior using patient level data to determine testing rates, methodology, and physician to lab relationship; DXRX Lab Mapping that offers insights into labs currently testing patients diagnosed with a specific disease or biomarker; and DXRX Disease Testing Rate Tracker, which delivers biomarker testing rate reports. In addition, the company offers scientific and advisory services. It operates in North America, the United Kingdom, Europe, Asia, and internationally. The company was incorporated in 2005 and is headquartered in Belfast, the United Kingdom.…
Industry Peers
Health Information ServicesKey Statistics
About Diaceutics (LON: DXRX)
›
Diaceutics (LON: DXRX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 205 employees.
The shares were at 190.00 GBp on 19 November 2026, up 15.9% over 52 weeks.
Its market capitalisation is 161.45M GBP.
Diaceutics reports return on equity of 0.2%, an operating margin of -1.9% and revenue up 19.9% year over year.
It holds more cash than debt, a net cash position of 6.01M GBP. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 240.00 GBp is 26.3% above the current price.